NEW YORK (GenomeWeb News) – Microfluidics firm Rheonix said this week it has received a $233,044 supplemental grant from the National Institutes of Health.
The grant supplements an earlier NIH award to develop a fully automated molecular diagnostic for detecting sexually transmitted infections, and expands the scope of the work to include the molecular detection of urinary tract infections. This week's award was given under the American Recovery and Reinvestment Act of 2009, more commonly known as the stimulus bill.
The point-of-care test being developed is based on Rheonix's flagship Chemistry and Reagent Device, or CARD, system. The technology allows all components of a multiplex molecular diagnosis to be integrated onto a 1 mm thick, palm-sized polystyrene chip, according to the company's website. Advanced fabrication methods and a proprietary manufacturing process are used to place a network of valves, channels, and reactors for an assay to be placed on the chip.
In a statement, Richard Montagna, senior vice president for scientific affairs at Rheonix and principal investigator on the project, said that the firm's production methods "will also permit the introduction of these POC devices at very competitive prices, thereby helping to reduce the growing cost of health care."
Last month, the Ithaca, NY-based company said that it intends to file an application with the US Food and Drug Administration for clearance of its warfarin sensitivity test based on the CARD system.